A randomized phase II study of systemic chemotherapy with and without trastuzumab followed by surgery in HER2 positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis (JCOG1301C:Trigger Study) - A randomized phase II study of systemic chemotherapy with and without trastuzumab followed by surgery in HER2 positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis (JCOG1301C:Trigger Study)

Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 130 人开始时间: 2015年3月26日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Synchronous or metachronous (within 5 years) malignancies except for carcinoma in situ or mucosal tumors curatively treated with local therapy. 2) Active infection requiring systemic therapy. 3) Body temperature >= 38 degrees Celsius. 4) Pregnancy, possible pregnancy or breastfeeding. 5) Psychiatric disease. 6) Patients requiring systemic steroid medication. 7) Positive HBs antigen 8) Under treatment with flucytosine, phenytoin, or warfarin. 9) Interstitial pneumonia, pulmonary fibrosis or severe emphysema. 10) Unstable angina within 3 weeks, or with a history of myocardial infarction within 6 months. 11) Poorly controlled hypertension. 12) Poorly controlled diabetes mellitus or routine administration of insulin.

发起方

Japan Clinical Oncology Group (JCOG)